AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20032789 — intervention group
Group type: EXPERIMENTAL
Intervention: PCB + S (25 mg daily, 2 weeks on, 1 week off)
Number of subjects: 56
Study 20032789 — intervention group
Group type: COMPARATOR
Intervention: PCB (15 mg/kg every 3 weeks)
Number of subjects: 56
Study 18722318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 453
Study 18722318 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 453
Study 15957562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure group condition (problem-solving skills training with all members having conduct problems)
Number of subjects: 139
Study 15957562 — intervention group
Group type: COMPARATOR
Intervention: Mixed group condition (problem-solving skills training with adolescents with and without behavior problems)
Number of subjects: 139
Study 12204648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser irradiation (HeNe, 632.8 nm) with a dose of 30 J/cm²
Number of subjects: 0
Study 12204648 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation (placebo)
Number of subjects: 0
Study 10494759 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with targeted INR of 2.0 to 2.5
Number of subjects: 21
Study 10494759 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with targeted INR of 1.5 to 1.9
Number of subjects: 21
Study 10494759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8610715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms)
Number of subjects: 213
Study 8610715 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol (5% solution, 15 mg)
Number of subjects: 213
Study 1487306 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-specific leukocyte immunotherapy
Number of subjects: 51
Study 1487306 — intervention group
Group type: COMPARATOR
Intervention: Own cells immunotherapy
Number of subjects: 51
Study 4035297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral water
Number of subjects: 0
Study 4035297 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study 4035297 — intervention group
Group type: COMPARATOR
Intervention: Exogenous infusions of porcine motilin (physiological and pharmacological)
Number of subjects: 0
Study 4035297 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 0
Study 31601166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of adequate knowledge of infection control procedures and disease transmission
Number of subjects: 450
Study 31601166 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance with infection control protocol of vaccination against hepatitis B virus
Number of subjects: 450
Study 31601166 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending 12 or less number of patients daily
Number of subjects: 450
Study 31601166 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in dental clinics without an infection control unit
Number of subjects: 450
Study 29549030 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 70
Study 29549030 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 29549030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 27114561 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus Methotrexate (ADA + MTX)
Number of subjects: 444
Study 27114561 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Methotrexate (PBO + MTX)
Number of subjects: 444
Study 24333035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) intervention
Number of subjects: 60
Study 24333035 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 24957431 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM but not DR (Group 2)
Number of subjects: 60
Study 24957431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with nonproliferative DR (Group 3)
Number of subjects: 60
Study 24957431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with proliferative DR (Group 4)
Number of subjects: 60
Study 24957431 — intervention group
Group type: COMPARATOR
Intervention: Patients without DM (Group 1)
Number of subjects: 60
Study 22207723 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (n = 11)
Number of subjects: 21
Study 22207723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 21
Study 19589288 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with Lavonase system (250 mL saline solution sac, twice daily for 14 days)
Number of subjects: 20
Study 19589288 — intervention group
Group type: COMPARATOR
Intervention: Nasal syringe (10 mL saline solution, 3 times daily for 14 days)
Number of subjects: 20
Study 17322603 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 30
Study 17322603 — intervention group
Group type: COMPARATOR
Intervention: Latoprost
Number of subjects: 30
Study 17322603 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalatan (after crossover from Latoprost)
Number of subjects: 30
Study 17322603 — intervention group
Group type: COMPARATOR
Intervention: Latoprost (after crossover from Xalatan)
Number of subjects: 30
Study 15257726 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM)
Number of subjects: 128
Study 15257726 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 128
Study 11190792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 11190792 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic relaxation
Number of subjects: 0
Study 11190792 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet rest
Number of subjects: 0
Study 11190792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (during physical challenges)
Number of subjects: 0
Study 11190792 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 0
Study 9825507 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucellar protein antigens with mol. weights of 18 kD
Number of subjects: 0
Study 9825507 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucellar protein antigens with mol. weights of 38 kD
Number of subjects: 0
Study 9825507 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucellar protein antigens with mol. weights of 18 kD and 38 kD
Number of subjects: 0
Study 7503405 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 17
Study 7503405 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide
Number of subjects: 17
Study 1955814 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0 mg, 7.5 mg, 15 mg, 30 mg/70 kg, p.o.)
Number of subjects: 3
Study 1955814 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0 mg, 0.375 mg, 0.75 mg/70 kg, p.o.)
Number of subjects: 3
Study 1955814 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing contingency present
Number of subjects: 3
Study 1955814 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing contingency with increased error requirements
Number of subjects: 3
Study 7134226 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg twice daily
Number of subjects: 12
Study 7134226 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 12
Study 7134226 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (both dosages)
Number of subjects: 12
Study 7134226 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (higher dosage)
Number of subjects: 12
Study 31575571 — intervention group
Group type: EXPERIMENTAL
Intervention: Active behavioural physiotherapy intervention (ABPI)
Number of subjects: 60
Study 31575571 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy intervention
Number of subjects: 60
Study 27832646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient supplementation (PROfertil® female) including folic acid, selenium, vitamin E, catechins, glycyrrhizin, diosgenin, damiana, omega‐3‐fatty acids; n = 50
Number of subjects: 100
Study 27832646 — intervention group
Group type: COMPARATOR
Intervention: 400 µg folic acid (control group); n = 50
Number of subjects: 100
Study 25301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) tools
Number of subjects: 123
Study 25301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 123
Study 25301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 123
Study 25301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient knowledge of medical condition and treatment options
Number of subjects: 123
Study 24144885 — intervention group
Group type: EXPERIMENTAL
Intervention: PICD
Number of subjects: 10
Study 24144885 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICD
Number of subjects: 10
Study 22532053 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT-G)
Number of subjects: 50
Study 22532053 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 20000066 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-zinc supplementation
Number of subjects: 156
Study 20000066 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Iron-only supplementation)
Number of subjects: 156
Study 17516966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose alone (n = 77)
Number of subjects: 147
Study 17516966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose combined with ispaghula husk (Fybogel group, n = 70)
Number of subjects: 147
Study 15161357 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-dose whole-body ionizing radiation exposure
Number of subjects: 45468
Study 11394601 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (running for 15 minutes on a neutral-incline treadmill)
Number of subjects: 103
Study 11394601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the state before exercise)
Number of subjects: 103
Study 9546804 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 0
Study 9546804 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and didanosine (ddI) therapy
Number of subjects: 0
Study 9546804 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8296698 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem
Number of subjects: 15
Study 8296698 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 15
Study 8296698 — intervention group
Group type: COMPARATOR
Intervention: nitrates
Number of subjects: 15
Study 8296698 — intervention group
Group type: COMPARATOR
Intervention: no therapy
Number of subjects: 15
Study 8296698 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol and diltiazem
Number of subjects: 15
Study 1707338 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 59
Study 1707338 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiation therapy and chemotherapy (RT + CT) with 5‐fluorouracil (5‐FU), mitomycin C, and bleomycin
Number of subjects: 59
Study 7009256 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional oxprenolol administered twice daily
Number of subjects: 20
Study 7009256 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol administered once daily
Number of subjects: 20
Study 7009256 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide 0.5 mg daily (in 16 patients)
Number of subjects: 20
Study 31790344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus best supportive care (BSC)
Number of subjects: 413
Study 31790344 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 413
Study 31790344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 413
Study 31790344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 30679138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol plus IVF
Number of subjects: 70
Study 30679138 — intervention group
Group type: COMPARATOR
Intervention: IVF alone
Number of subjects: 70
Study 27822982 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal protective clothing (TPC) and self‐contained breathing apparatus (SCBA) during exertion
Number of subjects: 0
Study 27822982 — intervention group
Group type: COMPARATOR
Intervention: Non-stressed conditions (without TPC and SCBA)
Number of subjects: 0
Study 27822982 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different SCBA cylinder masses
Number of subjects: 0
Study 25386670 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 115
Study 25386670 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 115
Study 25386670 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 115
Study 23356829 — intervention group
Group type: COMPARATOR
Intervention: Pelvic drainage removed on postoperative day 1 (Group 2)
Number of subjects: 331
Study 23356829 — intervention group
Group type: COMPARATOR
Intervention: Pelvic drainage removed on postoperative day 7 (Group 1)
Number of subjects: 331
Study 23356829 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Group 3)
Number of subjects: 331
Study 23356829 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted radical prostatectomy without drainage (Group 4)
Number of subjects: 331
Study 23356829 — intervention group
Group type: COMPARATOR
Intervention: Open RRP (Groups 1-3)
Number of subjects: 331
Study 23356829 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted RARP (Group 4)
Number of subjects: 331
Study 23356829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal-positive patients
Number of subjects: 331
Study 23356829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal-negative patients
Number of subjects: 331
Study 21249381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleuran (β-glucan from Pleurotus ostreatus)
Number of subjects: 50
Study 21249381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19742334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track surgery
Number of subjects: 92
Study 19742334 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional surgery)
Number of subjects: 92
Study 17535530 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 48
Study 17535530 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 48
Study 15581263 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with monitoring strips received during all three years (FYs 2000, 2001, and 2002)
Number of subjects: 976
Study 15581263 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with monitoring strips received in FY 2002 only
Number of subjects: 976
Study 15581263 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with monitoring strips received in FYs 2001 and 2002
Number of subjects: 976
Study 15581263 — intervention group
Group type: COMPARATOR
Intervention: No self-monitoring of blood glucose (SMBG) with monitoring strips
Number of subjects: 976
Study 11270701 — intervention group
Group type: EXPERIMENTAL
Intervention: CapSure Z lead (5034 bipolar)
Number of subjects: 89
Study 11270701 — intervention group
Group type: COMPARATOR
Intervention: CapSure SP lead (5024 bipolar)
Number of subjects: 89
Study 9709721 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal-conjugate vaccine plus 23-valent pneumococcal vaccine
Number of subjects: 0
Study 9709721 — intervention group
Group type: COMPARATOR
Intervention: 23-valent vaccine only
Number of subjects: 0
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy and/or tympanostomy tube insertion
Number of subjects: 2512
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting an ear, nose, and throat specialist
Number of subjects: 2512
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental exaggeration of the episodes
Number of subjects: 2512
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Having the first episode under 6 months of age
Number of subjects: 2512
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent respiratory tract infections
Number of subjects: 2512
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2512
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban domicile
Number of subjects: 2512
Study 8049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care
Number of subjects: 2512
Study 3276900 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with 5‐fluorouracil, semustine, and vincristine (MOF) (187 patients)
Number of subjects: 555
Study 3276900 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (4,600‐4,700 rad in 26‐27 fractions; 5,100‐5,300 rad maximum at the perineum) (184 patients)
Number of subjects: 555
Study 3276900 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (184 patients)
Number of subjects: 555
Study 31674929 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 63
Study 31674929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 63
Study 28729021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 450 mg with food
Number of subjects: 137
Study 28729021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 600 mg with food
Number of subjects: 137
Study 28729021 — intervention group
Group type: COMPARATOR
Intervention: Ceritinib 750 mg fasted
Number of subjects: 137
Study 26183691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Group (CVG; n=20)
Number of subjects: 80
Study 26183691 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Group (RG; n=20)
Number of subjects: 80
Study 26183691 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; n=20)
Number of subjects: 80
Study 26183691 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural Group (PG; n=20)
Number of subjects: 80
Study 23597539 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared light device
Number of subjects: 60
Study 21668683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ann Arbor strain live attenuated influenza vaccine (LAIV)
Number of subjects: 4245
Study 18269652 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin + gentamicin + nystatin sulfate orally (Group A)
Number of subjects: 91
Study 18269652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 91
Study 16528432 — intervention group
Group type: EXPERIMENTAL
Intervention: home-based intervention program
Number of subjects: 121
Study 14710913 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 28
Study 14710913 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 28
Study 14710913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11151578 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled abutments (0 to 15 degrees)
Number of subjects: 467
Study 11151578 — intervention group
Group type: COMPARATOR
Intervention: Angled abutments (20 to 45 degrees)
Number of subjects: 467
Study 8935222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg once daily)
Number of subjects: 12
Study 8935222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1392444 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (CDD/ANP‐95‐126) administered in a long‐term, low‐dose infusion (6‐20 ng/kg bw.min) for 96 hours after HTx
Number of subjects: 51
Study 4057974 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 1
Number of subjects: 6
Study 4057974 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 2
Number of subjects: 6
Study 4057974 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 3
Number of subjects: 6
Study 4057974 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 4
Number of subjects: 6
Study 4057974 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech sampling condition 5
Number of subjects: 6
Study 30987415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nebulization of 5 ml 1% ropivacaine before and after surgery
Number of subjects: 60
Study 30987415 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal instillation of 20 ml 0.5% ropivacaine after induction of pneumoperitoneum
Number of subjects: 60
Study 30987415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nebulization of 5 ml 1% ropivacaine
Number of subjects: 60
Study 29022100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn
Number of subjects: 18
Study 29022100 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry
Number of subjects: 18
Study 29022100 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 27304841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 24
Study 27304841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25144296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg and Candesartan cilexetil 32 mg
Number of subjects: 1381
Study 25144296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (any dose) and Candesartan cilexetil (any dose)
Number of subjects: 1381
Study 25144296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg and Candesartan cilexetil 4 mg
Number of subjects: 1381
Study 25144296 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS monotherapy
Number of subjects: 1381
Study 25144296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS plus Candesartan cilexetil combination therapy
Number of subjects: 1381